chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Lethargy, Rash
Clinical narrative: Neck rash; Lethargy; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021(at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021 the patient experienced lethargy. On 04Apr2021(morning), the patient experienced neck rash. It was unknown whether the patient received any treatment for the reported adverse events. The clinical outcome of the event lethargy and neck rash was unknown.   No follow-up attempts are possible. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Rash, Sunburn
Clinical narrative: Does not itch, feels like sunburn; Oblong pink rash about 4 inches long and 3 inches wide below the injection site; Inappropriate schedule of vaccine administered; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 30Mar2021 at 13:30 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included positional tachycardia. The patient had a history of allergy to lobster, mussels, latex and garlic. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 13Mar2021 at 13:45 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 03Apr2021 at 21:00, five days after vaccination the patient developed an oblong pink rash about 4 inches long and 3 inches wide below the injection site and she felt like sunburn but it did not itch. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events oblong pink rash about 4 inches long and 3 inches wide below the injection site and does not itch, feels like sunburn was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Malaise, Pyrexia
Clinical narrative: chills; Fever; felt sick; This is a spontaneous report received from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200), via an unspecified route of administration in the right arm on 01Mar2021 at 16:00 (at the age of 65-years-old), as a single dose for COVID-19 immunisation. Medical history included history of cancer which was cured. The patient had allergy to latex and oral steroids. Concomitant medications were reported as yes. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within four weeks prior to COVID vaccine. On 02Mar2021 at 04:00, the patient experienced chills, fever and felt sick and slept all day, felt better 2nd day but still felt like working at half power; and on 3rd day the patient was back to normal. The patient did not receive any treatment for the adverse events. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events chills and fever was resolved on an unknown date in 2021. The patent received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration in the right arm on 24Mar2021 at 12:00, as a single dose for COVID-19 immunisation.    No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Neck pain, Pain
Clinical narrative: Incredibly stiff and sore neck. Hurts to move in any direction and cannot move very far at all in any direction.; Incredibly stiff and sore neck.; Hurts to move in any direction and cannot move very far at all in any direction.; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737), via an unspecified route of administration in the left arm on 06Apr2021 at 15:30 (at the age of 29-years-old), as a single dose for COVID-19 immunisation. Concomitant medications included ethinylestradiol, levonorgestrel (LEVORA) from an unknown date for unknown indication. The patient previously took nitrofurantoin on unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 16:30, the patient experienced incredibly stiff and sore neck, hurts to move in any direction and cannot move far at all in any direction. The patient had a slightly sore neck this morning like the patient had slept on it wrong or something, but it wasn't very bothersome at all. About an hour after the vaccine, the patient felt the neck get very stiff and by two hours after the patient was in intense pain. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events incredibly stiff and sore neck, hurts to move in any direction and cannot move very far at all in any direction were not resolved at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Eczema nummular, Exfoliative rash, Nausea, Pruritus, Rash pruritic
Clinical narrative: Itching spread to right arm.; went to the dermatologist on 3/24 and was diagnosed with nummular eczema; After two weeks, spots began on the right leg. They were distinctive round shape about the size of a quarter or less. They were scaly; itchy bumps near elbow of left arm; extremely nauseous for 48 hours immediately following the vaccine; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Feb2021 at 10:00(at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergy. Concomitant medications included cetirizine hydrochloride (ZYRTEC, 10mg) taken within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccination. On 25Feb2021 the patient experienced extremely nauseous for 48 hours immediately following the vaccine. On 26Feb2021, at 14:00 after 28 hours following the vaccination, the patient experienced itchy bumps near elbow of left arm. After a few days, itching spread to right arm.  On an unknown date in Mar2021, after two weeks the patient experienced spots on the right leg. They were distinctive round shape about the size of a quarter or less. They were scaly. They got worse when the patient was hot or wearing stiff pants like jeans. The patient did not get the 2nd dose as scheduled.  On 24Mar2021 the patient was diagnosed with nummular eczema. Therapeutic measures included treatment with Steroid cream.  The event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event nausea immediately following the vaccine was recovered in 48 hours on 27Feb2021. The clinical outcome of the events itchy rash, itching, eczema nummular, scaly rash were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic
Clinical narrative: SMALL ITCHY RASH APPEARED NEAR THE INJECTION SITE; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 01Apr2021 at 14:00 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included osteoporosis, seasonal allergic rhinitis and penicillin allergy. Patient previously received anectine and experienced allergy. Concomitant medications included risedronate sodium (RISEDRONATE), estradiol (ESTRACE), macrogol 3350 (MIRALAX) and vitamin D (MANUFACTURER UNKNOWN) all for unknown indication and from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: GN6206) via an unspecified route of administration in the left arm on 11Mar2021 at 14:30 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021, at 19:00 after 5 days of vaccination, the patient experienced small itchy rash. It appeared on Tuesday and was about the size of a quarter near the injection site, but not where the needle went in. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event small itchy rash appeared near the injection site was unknown.    No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Lymphadenopathy, Myalgia
Clinical narrative: fever; chills; muscle soreness; swollen glands; fatigue; headache; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 31Mar2021 at 09:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. The patient did not receive any concomitant medications within two weeks prior to COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 03Mar2021 at 09:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 31Mar2021 at 20:30 the patient experienced fever, chills, muscle soreness, swollen glands, fatigue and headache. The patient wanted to report it because she experienced so many of the possible side effects. The adverse events had not resulted in a visit to the doctors or other healthcare professional office or clinic visit or emergency room or department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fever, chills, muscle soreness, swollen glands, fatigue and headache were recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: fever; chills; muscle soreness; swollen glands; fatigue; headache; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 31Mar2021 at 09:45 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. The patient did not receive any concomitant medications within two weeks prior to COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 03Mar2021 at 09:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 31Mar2021 at 20:30 the patient experienced fever, chills, muscle soreness, swollen glands, fatigue and headache. The patient wanted to report it because she experienced so many of the possible side effects. The adverse events had not resulted in a visit to the doctors or other healthcare professional office or clinic visit or emergency room or department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events fever, chills, muscle soreness, swollen glands, fatigue and headache were recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pyrexia
Clinical narrative: Fever; Chills; Headache; Body aches; This is a spontaneous report from a non-contactable consumer, the patient. A 48-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 28Mar2021 at 15:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food or other products. Concomitant medications included levocetirizine dihydrochloride (XYZAL) and cyclobenzaprine (MANUFACTURER UNKNOWN) for unknown indications from unknown start dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 07Mar2021 at 16:45 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 15:00 the patient experienced fever, chills, head ache and body aches. Therapeutic measures were taken as a result of adverse events included treatment with Tylenol. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, fever, chills and body aches was recovered on an unspecified date in 2021.  No follow-up attempts are possible. information about lot\batch number cannot be obtained.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Insomnia
Clinical narrative: Can't sleep; Bowel issues; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 11Mar2021 at 14:00  (at the age of 64-year-old)  and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 01Apr2021 at 14:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetic, high blood and osteoarthritis. The patient's history of known allergies was reported as none. The patient has taken unspecified concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Mar2021, the patient experienced insomnia and  bowel issues. The patient did not receive any treatment for the reported events. The adverse event resulted in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events insomnia and bowel issues were unknown at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Arthralgia, Lymph node pain, Lymphadenopathy, Myalgia
Clinical narrative: 103.9 fever; Muscle pain; Joint pain; Swollen lymph node in armpit; Stomach pain; Swollen lymph node in armpit that issharp pain and tender; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 02Apr2021 at 12:00(at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included polycystic ovarian syndrome. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and ethinylestradiol; norgestimate  (ESTARYLLA) on an unknown date for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient received unspecified other vaccine within four weeks prior to the vaccination. On 02Apr2021 at 22:00, the patient experienced 103.9 fever, muscle pain, joint pain, swollen lymph node in armpit that is sharp pain and tender and stomach pain. The patient did not receive any treatment for the events. Adverse events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. On 02Apr2021 at 22:00, the patient underwent lab test procedures which included body temperature and the result was 103.9 (unspecified units). The clinical outcome of the events 103.9 fever, muscle pain, joint pain, swollen lymph node in armpit that is sharp pain and tender and stomach pain was resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: 103.9 fever; Muscle pain; Joint pain; Swollen lymph node in armpit; Stomach pain; Swollen lymph node in armpit that issharp pain and tender; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 02Apr2021 at 12:00(at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included polycystic ovarian syndrome. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and ethinylestradiol; norgestimate  (ESTARYLLA) on an unknown date for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient received unspecified other vaccine within four weeks prior to the vaccination. On 02Apr2021 at 22:00, the patient experienced 103.9 fever, muscle pain, joint pain, swollen lymph node in armpit that is sharp pain and tender and stomach pain. The patient did not receive any treatment for the events. Adverse events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. On 02Apr2021 at 22:00, the patient underwent lab test procedures which included body temperature and the result was 103.9 (unspecified units). The clinical outcome of the events 103.9 fever, muscle pain, joint pain, swollen lymph node in armpit that is sharp pain and tender and stomach pain was resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Confusional state, Dyspnoea, Eye irritation, Fatigue, Headache
Clinical narrative: Extreme body aches; Headache; Fever; Nose burning; Memory trouble; Confusion; Lethargic; Burning eyes; Shortness of breath; Sore arms; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the left arm on 01Apr2021 at 11:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic cellulitis, fibromyalgia, chronic sinusitis, chronic bronchitis, achromobacter infection, prior septic shock, brain surgeries, breast reconstruction, staphylococcal infection (staph infections), stroke and sulphonamide allergy (sulfa allergy). Concomitant medications included ceftriaxone sodium (ROCEPHIN) taken on 15Mar2021 in the right hip for an unspecified indication, ceftriaxone sodium (ROCEPHIN) taken on 16Mar2021 in the left hip for an unspecified indication and amoxicillin sodium; clavulanate potassium (AUGMENTIN) 500 milligrams taken from an unknown date for an unknown indication. The patient previously received PAXIL, EFFEXOR, TOPIMAX, CYMBALTA and morphine and experienced a drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021, the patient experienced fatigue. On 02Apr2021, the patient experienced worsened fatigue and sore arms in the evening. On 03Apr2021 at 07:00, the patient experienced worsened fatigue, extreme body aches, a headache which was 7 on the pain scale that did not respond to medications, fever, nose burning, memory trouble, confusion, lethargic, burning eyes and shortness of breath. The patient reported that these events continued on the fourth day which was 04Apr2021. The patient reported that on 05Apr2021, the fifth day the patient still was fatigued and weak but there was some improvement. The events did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/ department or urgent care. The patient did not receive any treatments for the events experienced except for headache for which she took unspecified medications. The clinical outcome of the events fatigue, sore arms, body ache, headache, fever, nose burning, memory trouble, confusion, lethargy, burning eyes and shortness of breath were resolved with sequelae on an unspecified date in Apr2021 at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Lethargy, Memory impairment, Nasal discomfort, Pain, Pain in extremity
Clinical narrative: Extreme body aches; Headache; Fever; Nose burning; Memory trouble; Confusion; Lethargic; Burning eyes; Shortness of breath; Sore arms; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the left arm on 01Apr2021 at 11:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic cellulitis, fibromyalgia, chronic sinusitis, chronic bronchitis, achromobacter infection, prior septic shock, brain surgeries, breast reconstruction, staphylococcal infection (staph infections), stroke and sulphonamide allergy (sulfa allergy). Concomitant medications included ceftriaxone sodium (ROCEPHIN) taken on 15Mar2021 in the right hip for an unspecified indication, ceftriaxone sodium (ROCEPHIN) taken on 16Mar2021 in the left hip for an unspecified indication and amoxicillin sodium; clavulanate potassium (AUGMENTIN) 500 milligrams taken from an unknown date for an unknown indication. The patient previously received PAXIL, EFFEXOR, TOPIMAX, CYMBALTA and morphine and experienced a drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021, the patient experienced fatigue. On 02Apr2021, the patient experienced worsened fatigue and sore arms in the evening. On 03Apr2021 at 07:00, the patient experienced worsened fatigue, extreme body aches, a headache which was 7 on the pain scale that did not respond to medications, fever, nose burning, memory trouble, confusion, lethargic, burning eyes and shortness of breath. The patient reported that these events continued on the fourth day which was 04Apr2021. The patient reported that on 05Apr2021, the fifth day the patient still was fatigued and weak but there was some improvement. The events did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/ department or urgent care. The patient did not receive any treatments for the events experienced except for headache for which she took unspecified medications. The clinical outcome of the events fatigue, sore arms, body ache, headache, fever, nose burning, memory trouble, confusion, lethargy, burning eyes and shortness of breath were resolved with sequelae on an unspecified date in Apr2021 at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Extreme body aches; Headache; Fever; Nose burning; Memory trouble; Confusion; Lethargic; Burning eyes; Shortness of breath; Sore arms; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the left arm on 01Apr2021 at 11:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic cellulitis, fibromyalgia, chronic sinusitis, chronic bronchitis, achromobacter infection, prior septic shock, brain surgeries, breast reconstruction, staphylococcal infection (staph infections), stroke and sulphonamide allergy (sulfa allergy). Concomitant medications included ceftriaxone sodium (ROCEPHIN) taken on 15Mar2021 in the right hip for an unspecified indication, ceftriaxone sodium (ROCEPHIN) taken on 16Mar2021 in the left hip for an unspecified indication and amoxicillin sodium; clavulanate potassium (AUGMENTIN) 500 milligrams taken from an unknown date for an unknown indication. The patient previously received PAXIL, EFFEXOR, TOPIMAX, CYMBALTA and morphine and experienced a drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021, the patient experienced fatigue. On 02Apr2021, the patient experienced worsened fatigue and sore arms in the evening. On 03Apr2021 at 07:00, the patient experienced worsened fatigue, extreme body aches, a headache which was 7 on the pain scale that did not respond to medications, fever, nose burning, memory trouble, confusion, lethargic, burning eyes and shortness of breath. The patient reported that these events continued on the fourth day which was 04Apr2021. The patient reported that on 05Apr2021, the fifth day the patient still was fatigued and weak but there was some improvement. The events did not result in a doctor or other healthcare professional office/clinic visit, and emergency room/ department or urgent care. The patient did not receive any treatments for the events experienced except for headache for which she took unspecified medications. The clinical outcome of the events fatigue, sore arms, body ache, headache, fever, nose burning, memory trouble, confusion, lethargy, burning eyes and shortness of breath were resolved with sequelae on an unspecified date in Apr2021 at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Armpit swelling; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 31Mar2021 at 08:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. The patient did not receive any concomitant medications. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 12:00 the patient experienced armpit swelling. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event armpit swelling was not recovered at the time of the report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia oral, Pharyngeal swelling
Clinical narrative: Throat swelling; Tongue tingling; Numbness in back, mouth, hands, lips.; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153), via an unspecified route of administration in the left arm on 05Apr2021 at 09:30 (at the age of 33-years-old), as a single dose for COVID-19 immunisation. Medical history included chronic moderate asthma, allergies, shellfish allergy, peanut allergy and allergy to nuts. Concomitant medications included mometasone furoate (FLONASE), vitamin D nos (MANUFACTURER UNKNOWN), BREO 100 and fish oil supplements; all from an unknown date for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 11:00, the patient experienced throat swelling, tongue tingling, numbness in back, mouth, hands and lips. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events throat swelling, tongue tingling, numbness in back, mouth, hands and lips were resolving at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Nausea
Clinical narrative: Headache; Fatigue; Nausea; Chills; This is a spontaneous report from a non-contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 31Mar2021 at 10:30 (at the age of 60-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021, the patient experienced headache, fatigue, nausea and chills. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, fatigue, nausea and chills were not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Myalgia, Pyrexia
Clinical narrative: Fever for 1 day 100.4F; chills; arthralgia; myalgia; arm soreness (at the injection site); This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown), via an unspecified route of administration on an unknown date (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient was not diagnosed with COVID-19 prior to the vaccination. The patient had not been tested for COVID-19 since the vaccination. On 02Apr2021, the patient had experienced fever 100.4 degree fahrenheit for 1 day, chills, arthralgia, myalgia and arm soreness (at the injection site). The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken as the result of adverse events. The clinical outcome of the events fever for 1 day 100.4F, chills, arthralgia, myalgia and arm soreness (at the injection site) was resolved on an unknown date in Apr2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Fever for 1 day 100.4F; chills; arthralgia; myalgia; arm soreness (at the injection site); This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown), via an unspecified route of administration on an unknown date (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient was not diagnosed with COVID-19 prior to the vaccination. The patient had not been tested for COVID-19 since the vaccination. On 02Apr2021, the patient had experienced fever 100.4 degree fahrenheit for 1 day, chills, arthralgia, myalgia and arm soreness (at the injection site). The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken as the result of adverse events. The clinical outcome of the events fever for 1 day 100.4F, chills, arthralgia, myalgia and arm soreness (at the injection site) was resolved on an unknown date in Apr2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain
Clinical narrative: sore throat; This is a spontaneous report from a non-contactable consumer, the patient. A 50-year-old-non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: Unknown) via unspecified route of administration on 23Mar2021 at 09:30 (at the age of 50-years-old) as a single dose for COVID -19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 05:00, the patient experienced sore throat. it was reported that the patient got her shot 2 weeks ago and still had a sore throat and it was not getting any better. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. The clinical outcome of sore throat was not recovered at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Lymph node pain, SARS-CoV-2 test
Clinical narrative: Armpit very sore; lymph nodes very sore; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6208) via an unspecified route of administration in the arm left on 15Mar2021 at 16:15 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient did not have any allergies to medications, food, or other products. Concomitant medication included birth control , unspecified (MANUFACTURER UNKNOWN) on unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 12:00, the patient experienced arm pit and lymph nodes were very sore post vaccination. This occurred in her vaccination arm a week after the first dose. It was so painful it kept her awake at night . On 5Apr2021, the patient underwent lab test and procedures which included PCR test ( Sars cov-2 test)( test type: nasal swab)and the result was pending. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event.  The clinical outcome of the event lymph nodes very sore and armpit very sore were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Body temperature, Chills, Headache, Hot flush
Clinical narrative: Fever 101; Chills; Hot flashes; Terrible headache; Stomach pain; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 14:00(at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included mental disorder, difficult digestion and allergy to NSAIDS. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 04Apr2021 the patient experienced fever 101, chills, hot flashes, terrible headache, stomach pain and nausea. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, hot flashes, terrible headache, stomach pain and nausea were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pyrexia
Clinical narrative: Fever 101; Chills; Hot flashes; Terrible headache; Stomach pain; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 14:00(at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included mental disorder, difficult digestion and allergy to NSAIDS. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 04Apr2021 the patient experienced fever 101, chills, hot flashes, terrible headache, stomach pain and nausea. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, chills, hot flashes, terrible headache, stomach pain and nausea were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Dry skin, Rash, Skin reaction, Skin tightness, Swelling face
Clinical narrative: Skin reaction; Swelling of face; Dry skin; Tight skin; Rash on neck; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the left arm on 01Apr2021 at 09:00 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021, the patient experienced skin reaction, rash on neck, swelling of face, dry and tight skin.  Adverse events resulted in doctor/other health care professional office/clinic visit. The patient received treatment for the events with prednisone (MANUFACTURER UNKNOWN). The clinical outcome of the events skin reaction, rash on neck, swelling of face, dry and tight skin was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass, Chills, Fatigue, Headache
Clinical narrative: Swollen left underarm; Chills beginning at 5am the following day-headache-fatigue-swollen left underarm; Headache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 14:30 (at the age of 32-years-old) as a single dose for COVID-19 immunization. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Mar2021 at 14:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. On 04Apr2021 at 05:00 the patient experienced chills, headache, fatigue and swollen left underarm. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event chills, headache, fatigue and axillary mass was recovering at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Mass
Clinical narrative: Two mornings after the vaccine, I have a mass underneath my left arm. The size is a grapefruit.; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 31Mar2021 at 18:15 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. Medical history include penicillin (PCN) allergy. The patient previously received morphine (MANUFACTURER UNKNOWN) on an unspecified date for an unspecified indication and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation. The patient did not receive any other medications within 2 weeks of vaccination.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 07:00, two mornings after the vaccine, the patient experienced mass underneath the left arm. It was reported as a grapefruit size. The patient did not receive any treatment for the event. The event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event mass underneath the left arm was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.